cryopreserved arteries and 42 cryopreserved veins were implanted. Duration of primary patency was 354.0 6 241.3 days for the cryopreserved arteries and 358.2 6 481.1 days for the veins (P ¼ .11). Of the six arterial conduits used for a below-the-knee bypass, duration of primary patency was 212.4 6 103.8 days. Of the 36 venous conduits used for below-the-knee bypass, duration of primary patency was 366.6 6 465 days. By univariate analysis, there were no significant differences in characteristics of the patients between those who lost primary patency and those who did not (Table) . There was no statistical difference between donor variables: arterial or venous conduit, conduit diameter, WIT, blood type, Rhesus immunization, or seromatch. Donor blood type was not available for nine cases. Although not statistically significant, it appeared that tobacco use was clinically significant as 69% of failed primary patency patients were current smokers, whereas only 49% of those with continued patency were smokers (P ¼ .10). There was no statistically significant difference in primary patency by type of bypass or infrageniculate target. Time to loss of primary patency using Kaplan-Meier analysis demonstrates that cryopreserved femoral artery conduits were more likely to remain patent, and this trended toward significance (Fig; P ¼ .09) . Overall, the mean duration of primary patency with a venous conduit was 223 days, and the mean duration of primary patency with an arterial conduit was 267 days. After adjusting for indication, comorbid conditions (such as kidney disease, diabetes, and tobacco use), and type of bypass, risk-adjusted primary patency independently decreased with each hourly increase in WIT (hazard ratio [HR], 1.1; P ¼ .02). Femoral to femoral artery bypasses had the highest rate of primary patency (HR, 0.01; P ¼ .01), and popliteal-distal bypass had a much higher loss of patency (HR, 5.3; P ¼ 0.07). Cryoartery compared with cryovein did not independently predict patency in this population (HR, 0.7; P ¼ .60).
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Conclusions: This study reports the impact of cadaveric donor characteristics on the primary patency of cryopreserved vascular conduits used for lower extremity bypass. These data showed that primary patency decreased as WITs increased (HR, 1.1; P ¼ .02). Popliteal-distal bypasses had the worst primary patency, and bypasses in the femoral-femoral position had superior patency among the study population. These results provide additional insight into using cryopreserved conduits for these procedures. Overall primary patency at 1 year in this study was 26.1%, and this is analogous to other reports. In a series of 35 patients, Walker et al reported 28% patency in the same interval. The largest series to date, including 177 patients and 240 conduits, by Farber et al had a similar rate of 30% at 12 months. The finding of no significant increase in loss of primary patency with differing donor blood types is consistent with that of Walker et al. 4 However, other studies have found outcomes affected by ABO incompatibility. 3, 8 O'Banion et al found that ABO incompatibility was a significant risk factor for 30-day graft failure. Zehr et al reported that only 6 of 20 noncompatible grafts offered limb salvage. In other studies, centers seromatched all donor veins to recipients but did not find a difference between different donor blood type or Rh immunization and patency. 2, [5] [6] [7] Cryopreserved femoral arteries are much more robust tissue than saphenous vein, and the robust patency of arterial conduits compared with venous conduits in cardiac surgery is well known. Only a few studies have reported outcomes with cryopreserved arterial conduits, and these found a high rate of degeneration and loss of patency. In the current study, there was no significant difference in patency between artery and vein, even with below-the-knee bypass. A limitation of this study is that it may have been underpowered to demonstrate statistical significance. Duration of ischemia time is a known variable affecting outcomes in organ allotransplantation. Many techniques are currently used in clinical practice to condition organs that have been subject to extended ischemia times to improve outcomes. Considering this, it may not be surprising that longer ischemia times could affect graft patency from femoral arteries and saphenous veins harvested from cadaveric donors. However, this has not been previously reported in the vascular surgery literature and is a unique finding of the current analysis. Further studies should continue to evaluate the impact of ischemia time on patency to determine whether this factor will continue to have a role in graft patency and survival. Limitations of this study include its retrospective nature with inherent risk of selection bias as well as the limited number of patients (n ¼ 60). Clinical decisions should not be made on the basis of the results of a single study with limited subject numbers. Furthermore, the reported observations are merely associations between donor characteristics and primary patency; this does not imply a direct cause and effect relationship. In addition, the conduit diameters reported herein are from the product insert schematic; it is possible that intraoperative trimming could have affected the accuracy of these measurements. The current results indicate that increased WITs are associated with increased risk-adjusted loss of primary patency of lower extremity bypasses and reflect the outcomes of a single-institution cohort of vascular surgery patients. Larger future analyses related to the impact of donor characteristics on cryopreserved conduits are warranted because of the potential to significantly affect patient outcomes.
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The Implementation of a Pulmonary Embolism Response Team in the Management of Pulmonary Embolism
Eleftherios S. Xenos, George Davis, Amanda Green, Qiang He, Susan Smyth. University of Kentucky Medical Center, Lexington, Ky
Background: Massive and submassive pulmonary embolism (PE) can be life-threatening. Management options include anticoagulation, systemic fibrinolysis, and interventional treatment with catheter-directed or open surgical thrombus removal with or without extracorporeal membrane oxygenation. Currently, most patients with PE, even if they are hemodynamically unstable, are treated with anticoagulation alone. With increasing patient complexity and several therapeutic options, the optimal approach for patients with intermediate-to highrisk PE is not clearly established. The implementation of a clinical pathway executed by a multidisciplinary, rapid response team can optimize risk stratification and expedite management. To this end, the PE response team (PERT) was created at our institution with specialists from vascular surgery, critical care, interventional radiology, emergency medicine, cardiac surgery, and cardiology. The team used current evidence, knowledge, and recommendations as well as institutional experience to reach consensus and to create a risk stratification and treatment algorithm for management of patients with massive and submassive PE. The team is organized as a rapid response team and is activated with a 24-hour telephone number to evaluate and to treat these patients using the algorithm. We review our initial experience with this approach.
Methods: The records of patients who were treated by the PERT in 2016 (inception late 2015) and 2017 were reviewed (intervention group). The diagnosis codes of these patients were retrieved from the Vizient database, and a retrospective control cohort group was created using Results: There were 77 patients treated by activation of the PERT pathway; 992 patients were included in the control group, and these patients were treated at the discretion of an attending physician without use of the algorithm from October 2013 to 2016. Both groups had similar demographics, similar distribution of risk of mortality and severity of illness, and similar average Medicare Severity Diagnosis Related Group weighting. There was no statistically significant difference in the mortality rate between the two groups. The PERT group had significantly lower intensive care unit stay and overall length of stay. No difference was seen in direct cost between the two groups. The results are summarized in the Table. There was higher utilization of interventional treatment in the PERT group (57% vs 40% for control).
Conclusions: In our institution, patients with massive or submassive PE are managed by a dedicated team that implements a clinical algorithm developed by the team. This results in expedited treatment and reduced variation of care. Intensive care unit stay and overall length of stay are reduced by this approach, and the direct cost is not increased despite the use of advanced modalities of treatment. We believe that this paradigm can be of potential value in other disease entities, particularly when multiple disciplines are involved.
Author Disclosures: E. S. Xenos: Nothing to disclose; G. Davis: Nothing to disclose; A. Green: Nothing to disclose; Q. He: Nothing to disclose; S. Smyth: Nothing to disclose. Background: Segmental arterial mediolysis (SAM) is a poorly understood, nonatherosclerotic, noninflammatory disease resulting from degeneration of the arterial media. Patients may present with aneurysm, dissection, stenosis, or bleeding from visceral or renal arteries. Indications for intervention have been poorly characterized.
Natural History and Management Outcomes of Segmental Arterial Mediolysis
Methods: A retrospective review of all patients with a diagnosis of SAM was undertaken at a single institution in multiple geographic locations. Patients were identified using established criteria for the diagnosis of SAM (Table) , which excluded those diagnosed with fibromuscular dysplasia. Basic demographics, presenting symptoms, diagnostic evaluation, and outcomes were reviewed.
Results: Between 2004 and 2014, there were 116 patients diagnosed with SAM; 78 (67%) were male, with a mean age of 52.5 years (range, 23-90 years). There were 76 (65.5%) patients who presented with abdominal pain, 21 (18.1%) with flank pain, 18 (15.5%) with back pain, and 11 (9.5%) with hematuria; 16 (13.8%) patients had acute hypertension and 7 (6.0%) had hypotension. Thirteen (11.2%) patients presented with abdominal pain >30 days in duration. Twelve (10.3%) patients were asymptomatic.
Imaging revealed dissection in 96 (82.8%) patients, aneurysm in 49 (42.2%), stenosis in 24 (20.7%), occlusion/thrombosis in 18 (15.5%), pseudoaneurysm in 12 (10.3%), hemorrhage in 9 (7.8%), and arteriovenous fistula in 1 (0.9%). Disease location was renal in 57 (49.1%) patients, celiac in 51 (44.0%), superior mesenteric in 48 (41.4%), hepatic in 23 (19.8%), splenic in 18 (15.5%), inferior mesenteric in 3 (2.6%), and pancreatic in 3 (2.6%). Forty-five (38.8%) patients demonstrated evidence of end-organ ischemia.
Twenty Indications included large aneurysm in 12 patients (41.4%), end-organ ischemia in 9 (31.0%), hemorrhage in 6 (20.7%), and chronic pain in 2 (6.7%). There was one perioperative death. Presence of dissection was associated with successful medical management (P ¼ .0007). Statistically significant variables associated with need for intervention included pseudoaneurysm (P ¼ .002) and hemorrhage (P ¼ .0003).
There were 109 (94%) patients who underwent serial imaging, with mean follow-up of 37.2 months (range, 0-197.2 months). Nine (8.3%) patients had progression of radiologic findings and 17 (15.6%) had new findings seen in a different artery. Presentation of patients with acute abdominal pain was the only statistically significant variable associated with new findings on subsequent imaging (P ¼ .03).
Conclusions: SAM remains an uncommon yet important disease process that may require intervention. Therefore, it is important that the vascular surgery community be aware of this disease. Patients with SAM presenting with dissection are more likely to avoid invasive intervention. Those presenting with pseudoaneurysm and hemorrhage are more likely to fail to respond to medical management, and intervention should be considered. Serial imaging is imperative to identify disease progression, especially in those patients who present with acute abdominal pain. Background: Acute mesenteric ischemia (AMI) is a challenging clinical problem associated with significant morbidity and mortality. Despite increasing adoption of endovascular strategies to manage AMI, few contemporary reports focus on patients undergoing open mesenteric bypass (OMB). This is notable because there is a subset of patients who are poor candidates for peripheral intervention, including those with flush aortic visceral vessel occlusion, long-segment occlusive disease, and thrombosed mesenteric stents or bypass. Historical reports identify a retrograde OMB configuration as the safest choice because of the perception that an antegrade approach has higher risk. The purpose of this analysis was to review our experience with OMB and to compare outcomes of antegrade and retrograde OMB in the treatment of AMI.
Methods: A single-center, retrospective chart review was performed to identify all patients who underwent OMB for AMI from 2002 to 2016. Preoperative history of mesenteric revascularization, demographics, comorbidities, operative details, and outcomes were abstracted. The primary end point was in-hospital mortality. Secondary end points included 
